Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Metabolon Launches Fourth Generation DiscoveryHD4™ Metabolomics Platform

Published: Saturday, April 05, 2014
Last Updated: Saturday, April 05, 2014
Bookmark and Share
New technology advancements have potential to lead the way to new scientific breakthroughs, novel biomarkers and discoveries, and support diagnostic product pipeline.

Metabolon, Inc. has announced the launch of DiscoveryHD4™, the company’s fourth-generation metabolomics platform.

This new technology platform will empower the company's metabolomics TrueVision™, mVision™ and mView™ research and biomarker discovery offerings, as well as its diagnostic product development pipeline.

Further extending Metabolon's leadership position in metabolomics research and diagnostics, this platform enables a more expansive and precise global biochemical coverage of metabolite markers across the entire metabolome, thus increasing the ability to discover novel biomarkers and research questions.

Two key innovations power the DiscoveryHD4™ platform advancements. First, accurate mass instrumentation coupled to our new software technology provides a profound increase in sensitivity, and leads to the detection of more metabolites with greater precision.

Second adding a hydrophilic interaction chromatography (HILIC) method to the company’s standard platform technology provides a more complete picture for metabolites within central carbon, or “energy,” metabolism, among other advances.

The novel software tools that Metabolon has pioneered leverages these technical advancements. Together with Metabolon’s wealth of biochemistry expertise, these advancements are significant ingredients to Metabolon’s leadership and success in metabolomics.

“This new technology platform advances the evolution of our metabolomics capabilities and intellectual property,” said John Ryals, Ph.D, President and CEO of Metabolon. “These capabilities are a primary reason we are seeing more collaborations with large initiatives such as the one we recently announced with Craig Venter’s new genomics initiative, Human Longevity Inc. There is growing recognition of the value metabolomics offers to empower genomics and connect genetics to the phenotype, or the living system’s observable characteristics. Having a metabolomics technology platform with an industrialized capability and a capacity that can keep pace with the power of modern sequencing technologies is important to maintaining our position of industry leadership. The breadth of metabolome coverage that this new platform now provides enables more mechanistic insight into the basis of human health and disease.”

“Our scientists are ecstatic about the enhanced resolving power that the DiscoveryHD4™ will deliver our clients across academia and the biotechnology industry. We are already leveraging the enhanced resolving power of the new platform to fuel our diagnostic biomarker discovery pipeline,” commented Michael Milburn, Ph.D., Chief Scientific Officer of Metabolon.

Milburn continued, “Not only are we able to identify more metabolite markers than ever before, we have extended our capabilities to routinely measure additional classes such as steroids and energy metabolites. With these advancements, we can take a complex sample, such as blood, and rapidly identify and rigorously quality control up to 1,000 metabolites in a single biological sample, more than many have thought possible. Practically, this means our potential to discover more sensitive and specific biomarkers and understand what these signatures mean for the underlying biology is dramatically heightened.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Study Shows Quantose IR™ Measures Insulin Sensitivity Better
Results were recently published online by the Journal of Clinical Endocrinology & Metabolism.
Wednesday, April 01, 2015
Metabolon, Baylor Partner to Screen for Inborn Errors of Metabolism
The two-year, exclusive agreement will provide global Metabolomic-Assisted Pathway Screening (MAPS) services for individuals with suspected inborn errors of metabolism (IEMs).
Thursday, September 04, 2014
Metabolon, Geisinger Partner on Prediabetes Study
Metabolon will sponsor a pilot study to evaluate its Quantose IRTM test as a monitor of glycemic control in people with prediabetes.
Friday, June 27, 2014
New Study Reveals Interplay between Genetics and Metabolism in Complex Disease
Metabolomic profiling coupled with genomics data yields new insight into diseases, potential biomarkers and drug treatments.
Saturday, May 17, 2014
Interplay between Genetics and Metabolism in Complex Disease Revealed
Metabolomic profiling coupled with genomics data yields new insight into diseases, potential biomarkers and drug treatments
Friday, May 16, 2014
Metabolon Enters into Collaboration with GSK
Agreement will see Metabolon provide metabolomic profiling services to GlaxoSmithKline.
Wednesday, May 14, 2014
Metabolon Debuts New Client Portal at Bio-IT World Expo
MetaboLync™ is a cloud-based solution for sharing, visualizing, and analyzing metabolomics data.
Wednesday, April 30, 2014
Microbes and Metabolites Fuel an Ambitious Aging Project
Craig Venter’s new company wants to improve human longevity by creating the world’s largest, most comprehensive database of genetic and physiological information.
Wednesday, March 12, 2014
Collaboration Agreement to provide Metabolomic Profiling Services
Metabolon Inc will assist Human Longevity Inc to build the world’s largest and most complete human genotype, microbiome and phenotype database.
Wednesday, March 05, 2014
Metabolon Closes $15 Million Series E Financing
Company raises $15 million through the issuance of preferred stock.
Monday, January 06, 2014
Global Genomics Group and Metabolon to Collaborate
Metabolon will conduct biochemical profiling in single largest prospective pan-omic study.
Thursday, November 14, 2013
Metabolon and Bostwick Laboratories Announce Marketing Agreement
Under the Agreement Bostwick will market Prostarix™, a non-invasive urine test for stratifying prostate cancer risk.
Monday, November 04, 2013
Metabolon Announces Findings from Two Major Diabetes Outcomes Studies
This provides further evidence that the Quantose test identifies individuals at risk for type 2 diabetes earlier and more accurately than traditional risk factors alone.
Tuesday, June 25, 2013
Impaired Metabolism in Cystic Fibrosis Lung Epithelial Cells Revealed by Metabolic Analysis
Metabolon announces publication of “Metabolomic Profiling Reveals Biochemical Pathways and Biomarkers Associated with Pathogenesis in Cystic Fibrosis Cells”.
Monday, October 25, 2010
Metabolon Awarded US Patent for Metabolic Biomarkers of Efficacy of PPAR Affecting Drugs
The USPTO awarded the patent to Metabolon on October 5, 2010.
Thursday, October 21, 2010
Scientific News
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Circadian Clock Controls Insulin and Blood Sugar in Pancreas
Map of thousands of genes suggests new therapeutic targets for diabetes.
Cellular Stress Process Identified in Cardiovascular Disease
Combining the investigative tools of genetics, transcriptomics, epigenetics and metabolomics, a Duke Medicine research team has identified a new molecular pathway involved in heart attacks and death from heart disease.
Predicting Adverse Drug Reactions with Higher Confidence
A new integrated computational method helps predicting adverse drug reaction—which are often lethal—more reliably than with traditional computing methods.
A New Way to Starve Lung Cancer?
Metabolic alterations in lung cancer may open new avenues for treating the disease.
Evidence of How Incurable Cancer Develops
Researchers in the West Midlands have made a breakthrough in explaining how an incurable type of blood cancer develops from an often symptomless prior blood disorder.
Building a Better Liposome
Computational models suggest new design for nanoparticles used in targeted drug delivery.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos